SPIKEVAX^TM XBB.1.5

SPIKEVAX™ XBB.1.5

(andusomeran mRNA vaccine)

Resources for Canadian Healthcare Professionals and Patients

SPIKEVAX® XBB.1.5 (andusomeran mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.

The National Advisory Committee on Immunization (NACI) strongly recommends a dose of the new formulation of COVID-19 vaccine for individuals in the authorized age group if it has been at least 6 months from the previous COVID-19 vaccine dose or known SARS-CoV-2 infection (whichever is later). Immunization is particularly important for those at increased risk of COVID-19 infection or severe disease, for example: 

• Adults 65 years of age or older 

• Residents of long-term care homes and other congregate living settings 

• Individuals with underlying medical conditions that place them at higher risk of severe COVID-19 

• Individuals who are pregnant 

• Individuals in or from First Nations, Métis and Inuit communities* 

• Members of racialized and other equity-deserving communities 

• People who provide essential community services 

Click here for the full NACI recommendation as of July 11, 2023.

The current SPIKEVAX XBB.1.5 vial and carton labels are not Canadian-specific, as global, English-only labels are being used for the Canadian market.  

For more information, please see the Notice of English-Only Labelling below. 

Please find helpful resources for SPIKEVAX XBB.1.5 below. Check back as we update with additional educational content as it becomes available. 

0.10 mg/mL Drug Identification Number (DIN): 02541270

* Autonomous decisions should be made by Indigenous Peoples with the support of healthcare and public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples.